Rema Sanghavi, DO
Family Medicine · O Fallon, ILNPI 1104991017
Payments from drug & device makers
Across 414 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$902
- Novo Nordisk$617
- AbbVie$504
- Boehringer Ingelheim$467
- Amgen$463
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,311100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 73 | $1,624 |
| Lilly USA, LLC | 55 | $902 |
| Novo Nordisk | 44 | $617 |
| AbbVie(2 entities) | 41 | $504 |
| Boehringer Ingelheim | 24 | $467 |
| Amgen | 26 | $463 |
| Pfizer | 46 | $429 |
| GSK | 9 | $222 |
| Johnson & Johnson | 12 | $217 |
| Axsome Therapeutics, Inc. | 4 | $190 |
| Biogen | 8 | $177 |
| Intuitive Surgical | 2 | $174 |
| Daiichi Sankyo Inc. | 7 | $134 |
| Dexcom, Inc. | 5 | $94 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| Eisai Inc. | 4 | $78 |
| Tris Pharma Inc | 4 | $76 |
| Exact Sciences | 4 | $66 |
| Esperion Therapeutics, Inc. | 1 | $66 |
| Abbott | 3 | $62 |
| Bayer | 4 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $58 |
| Nestle Healthcare Nutrition Inc. | 3 | $55 |
| Amarin Pharma, Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Novartis | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Lundbeck LLC | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$460
- BREZTRI$460
- AIRSUPRA$340
- Da Vinci Surgical System$121
- Symbravo$111
How this compares
$7,311 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 69 | $95,079 |
| RybelsusSemaglutide | 38 | $52,393 |
| FarxigaDapagliflozin Propanediol | 37 | $49,490 |
| MounjaroTirzepatide | 37 | $49,083 |
| OzempicSemaglutide | 41 | $44,151 |
| TrulicityDulaglutide | 40 | $43,919 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,309 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $13,911 |
| EliquisApixaban | 19 | $10,782 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,388 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $5,152 |
| Atorvastatin Calcium | 311 | $3,548 |
| Ramelteon | 12 | $2,494 |
| Klor-ConPotassium Chloride | 12 | $2,422 |
| Omeprazole | 122 | $2,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $467 | $108,99085 claims |
| Novo NordiskRybelsus, Ozempic | $617 | $96,54579 claims |
| Lilly USA, LLCMounjaro, Trulicity | $902 | $93,00277 claims |
| AstraZenecaFarxiga, Symbicort | $1,624 | $55,87962 claims |
| GSKTrelegy Ellipta | $222 | $16,30925 claims |
| PfizerEliquis | $429 | $10,78219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in O Fallon
- Kevin PritchettO Fallon$120K
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.